Advertisement
U.S. markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.3100+0.3000 (+14.93%)
At close: 04:00PM EST
2.2800 -0.03 (-1.30%)
After hours: 07:54PM EST
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
0
0
0
0
0
Operating Expense
18,835
20,090
18,129
14,766
2,818
Operating Income
-18,835
-20,090
-18,129
-14,766
-2,818
Net Non Operating Interest Income Expense
18.373
1,061
74.453
-19.923
-29.402
Pretax Income
-18,817
-19,029
-18,054
-14,786
-2,848
Net Income Common Stockholders
-18,817
-19,029
-18,054
-14,786
-2,848
Diluted NI Available to Com Stockholders
-18,817
-19,029
-18,054
-14,786
-2,848
Basic EPS
-3.99
-3.57
-4.28
-4.86
-2.10
Diluted EPS
-3.99
-3.57
-4.28
-4.86
-2.10
Basic Average Shares
4,830
5,333
4,223
3,035
1,369
Diluted Average Shares
4,830
5,333
4,223
3,035
1,369
Total Operating Income as Reported
-18,835
-20,090
-18,129
-14,766
-2,818
Total Expenses
18,835
20,090
18,129
14,766
2,818
Net Income from Continuing & Discontinued Operation
-18,817
-19,029
-18,054
-14,786
-2,848
Normalized Income
-18,817
-19,029
-18,054
-14,786
-2,848
Interest Income
498.685
1,061
74.453
-
-
Interest Expense
0.163
-
-
19.923
29.402
Net Interest Income
18.373
1,061
74.453
-19.923
-29.402
EBIT
-18,817
-20,090
-18,129
-14,766
-2,818
EBITDA
-18,817
-19,912
-18,122
-14,766
-2,818
Reconciled Depreciation
26.273
177.398
6.723
0
-
Net Income from Continuing Operation Net Minority Interest
-18,817
-19,029
-18,054
-14,786
-2,848
Normalized EBITDA
-18,817
-19,912
-18,122
-14,766
-2,818
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0